Neomorph, Inc. entered into a collaboration and licensing agreement with Novo Nordisk to discover, develop and commercialize molecular glue degraders. Neomorph is a biotechnology company working to discover novel therapeutics against ‘undruggable’ targets.
 
Neomorph will receive an upfront and near-term milestone payments, plus R&D funding. Neomorph is also eligible to receive future clinical, commercial and sales milestones bringing the total potential deal value for multiple targets to $1.46 billion, plus tiered royalties. Neomorph will lead discovery and preclinical activities against selected targets with Novo Nordisk having the right to exclusively pursue further clinical development and commercialization of the compounds.
 
“We are incredibly excited to partner with Novo Nordisk, a world-class healthcare company within diabetes, obesity and rare blood disorders,” said Phil Chamberlain, DPhil, Co-Founder, President, and CEO of Neomorph. “By combining Neomorph’s proprietary glue discovery platform with Novo Nordisk’s vast experience in cardiometabolic and rare diseases, we are well positioned to develop transformative treatments in these areas. This collaboration will enable the expansion of our platform into new therapeutic areas, complementing our on-going efforts in oncology.”
 
“Novo Nordisk is expanding its drug discovery efforts and deploying a range of novel technology platforms with the aim of discovering and developing new treatment solutions for people living with serious chronic diseases. We are pleased to enter this research collaboration and eager to start the scientific work on the novel class of molecular glue degraders being pioneered by Neomorph,” said Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk.